<DOC>
	<DOCNO>NCT02030613</DOCNO>
	<brief_summary>The purpose study determine optimal dosage etanercept patient treated idiopathic juvenile arthritis</brief_summary>
	<brief_title>Effective Dose Etanercept Patients Treated Juvenile Idiopathic Arthritis</brief_title>
	<detailed_description>Etanercept , fully human soluble tumor necrosis factor ( TNF ) receptor fusion protein , demonstrate safe efficacious treatment patient polyarticular JIA . However , many patient experience primary secondary response failure , suggest individualization treatment regimen may beneficial . It show clinical response two anti-TNFalpha biological agent ( infliximab , adalimumab ) closely follow trough drug level presence antibody direct drug . This study undertaken investigate whether serologic monitoring etanercept bioavailability immunogenicity individual patient JIA would useful optimize treatment regimen improve efficacy tolerability</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patient Juvenile Idiopathic Arthritis Age &lt; 18 year &gt; 4 year ( correspond pediatric AMM ) Patient Etanercept treatment context usual care , whatever dose ( dose remain stable weight study period ) . The patient must receive least one injection etanercept participate study . Signature consent guardian child Patient affiliate entitle social security scheme Infection progressive Pregnancy lactation . For adolescent reproductive age sexually active , contraception use duration treatment etanercept Contraindication treatment Etanercept Refusal study</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>juvenile idiopathic arthritis</keyword>
	<keyword>etanercept</keyword>
</DOC>